🏢 公司Newsroom01801Doubao · 实盘不做把握 7/10不做原因:消息已过时
北京时间·🕒 发布 16:16:32时区推断·⟳ 抓取 16:17:32回填·⚡ 决策 10-08 16:18:52·19.0 天前
信达生物 IBI3003（GPRC5D/BCMA/CD3 三抗）在 IMS 2026 公布复发难治多发性骨髓瘤 I 期更新数据，RP2D 360μg/kg 下 ORR 84.6%
公司新闻稿落款 2026-09-29，系 IMS 2026 年会口头报告的 I 期剂量优化更新，至信号研判时点（2026-10-08）已过去 9 天，数据在会议窗口期即可被市场获得；本次为小样本 I 期更新而非新的关键 topline，IBI3003 已进入 III 期注册阶段，无状态迁移级增量，短线无剩余 edge。
📄 原文01801↗ 原文
SAN FRANCISCO and SUZHOU, China , Sept. 29, 2026 -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a biopharmaceu…
不做 信达生物（01801.HK）
新闻稿为 2026-09-29 IMS 年会的 I 期小样本更新（RP2D 组 n=26），至研判日已过 9 天，资产已进入 III 期、无状态迁移级新增事实；当日港股收跌 5.03%，事件驱动窗口已关闭，无剩余 edge，不做
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
IBI3003 I 期数据疗效信号积极（RP2D 组 ORR 84.6%、MRD 阴性率 100%），但属 9 天前 IMS 会议的小样本更新，资产早已进入 III 期，无新增预期差；信达生物港股当日反而下跌 5.03%，不具备事件驱动的可交易窗口，回避。
🔎 新鲜度:最早出现 2026-09-29 · 扩散 medium · price-in 风险 high ↗
关键理由
- 数据本身正面：360 μg/kg 剂量下深度缓解与 MRD 阴性信号突出，安全性可控，支持 III 期推进
- 但催化时点已过：新闻稿 2026-09-29 发布、数据截止 2026-06-30，属会议常规更新而非新读出，市场已有充足消化时间
主要风险
- I 期 RP2D 组仅 26 例、随访 7.57 个月，疗效与持久性需 III 期验证，存在不及预期风险
- 若后续 TriadicMM-1 III 期出现阳性 topline 或对外授权（BD）交易，将构成独立的新催化，需重新研判
反向证据
- 做多前查反向 · 来源 web · 日期 2026-10-08 · 影响 weakens
行情显示 01801.HK 当日跌 5.03%、近 20 日 -5.7%，无证据表明市场将该旧数据作为新增利好定价；不支持在数据发布 9 天后追多
检索:信达生物 IBI3003 近期利空 砍单 下调 竞争 BCMA GPRC5D 三抗
先例如何影响了这次决策
对本次决策的影响:先例不改变结论：STALE 与无新增预期差已足以回避，无需再以历史涨幅支撑买点
方向:无可用于校准的同机制先例，但数据方向（ORR 84.6%、安全性可控）对资产本身偏正面
涨幅量级:缺乏高相似、锚点干净的同市场 I 期会议数据先例，无法据此校准短线涨幅
形态:未进行先例定价，因本次为 9 天前的旧会议更新，时效约束已先于幅度判断否决交易
工具执行结果 · 成功 3 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 13 ms
{"result": "search_processed_events:agent query=`innovent ibi3003 rp2d 360 μg/kg phase 1 data multiple myeloma ims annual meeting | 信达生物 ibi3003 三特异性抗体 gprc5d bcma cd3 多发性骨髓瘤 ims 2026 一期数据`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消息首发或不是重复；按当前事件继续 - fetch_decision_experience 成功 stock_tools HTTP · 9 ms
{ - stock_quote 成功 stock_tools HTTP · 5,033 ms
{
原文全文
展开原文 · 12,724 字
SAN FRANCISCO and SUZHOU, China , Sept. 29, 2026 -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of innovative medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology, and other major diseases, announced updated Phase 1 clinical data for IBI3003, a novel trispecific antibody targeting GPRC5D, BCMA, and CD3, in patients with relapsed or refractory multiple myeloma (R/R MM) in an oral presentation at the 23rd International Myeloma Society (IMS) Annual Meeting 2026. Based on the results of the Phase 1 dose optimization study, the recommended Phase 2 dose (RP2D) of IBI3003 was determined to be 360 μg/kg. At the RP2D, IBI3003 demonstrated rapid, deep, and durable response signals, particularly in heavily pretreated, high-risk patients with extramedullary disease.
IBI3003 is a novel trispecific antibody targeting G protein-coupled receptor C5D (GPRC5D), B-cell maturation antigen (BCMA), and CD3. Its dual-targeting design against BCMA and GPRC5D is intended to overcome tumor escape caused by the loss or downregulation of a single tumor antigen. In preclinical mouse models, IBI3003 demonstrated superior in vivo anti-tumor activity compared with marketed benchmark bispecific antibodies targeting GPRC5D/CD3 or BCMA/CD3, with particularly prominent tumor-killing activity in in vitro cell models with low expression of BCMA and GPRC5D. Currently, Innovent is conducting Phase 1/2 clinical trials of IBI3003 in China, Australia, and the United States (NCT06083207 and NCT07336472) to evaluate its safety, tolerability, and preliminary efficacy in patients with R/R MM. In parallel, Innovent has advanced the Phase 3 TriadicMM-1 study (NCT07623798) in China for IBI3003 in patients with R/R MM who have received 1 to 4 prior lines of therapy. In addition, the Phase II study of IBI3003 combined with CD38 monoclonal antibody for frontline MM is also ongoing (NCT07764861).
The updated data were from the Phase 1 clinical study NCT06083207, which enrolled eligible patients with R/R MM who had failed at least two prior lines of therapy, including at least one proteasome inhibitor (PI), one immunomodulatory drug (IMiD), and one anti-CD38-based therapy, and who had relapsed or were refractory to their last anti-myeloma regimen. Patients with prior BCMA- and/or GPRC5D-targeted therapy were also eligible for enrollment. IBI3003 was administered subcutaneously once weekly (QW). Patients who received continuous treatment for ≥6 months and achieved a partial response (PR) or better for ≥2 months could switch to once-every-two-weeks (Q2W) dosing for maintenance. To reduce the risk of cytokine release syndrome (CRS), 1 to 3 priming doses were incorporated into the study design.
A total of 102 patients were enrolled in this phase of the study in China and Australia, with doses ranging from 0.1 μg/kg to 800 μg/kg. The median patient age was 62 years (range: 40-88), 37.1% of patients were classified as high risk according to mSMART criteria, and 53.9% had ≥1 site of extramedullary disease (EMD). The median number of prior lines of therapy was 4 (range: 2-12). All patients had received at least three classes of therapy, including a PI, an IMiD, and an anti-CD38 antibody. Among them, 55.9% had received at least five classes of therapy, including at least two PIs, two IMiDs, and one anti-CD38 antibody; 33.3% had previously received anti-BCMA and/or anti-GPRC5D therapies; and 88.2% were refractory to their last treatment. As of the data cutoff date of June 30, 2026, the median follow-up duration was 6.65 months (range: 0.8-15.2).
Rapid, Deep, and Durable Responses Observed with IBI3003 at 360 μg/kg
Based on an integrated analysis of the efficacy, safety, and pharmacokinetic/pharmacodynamic (PK/PD) data from dose optimization cohorts receiving IBI3003 at 120, 360, and 540 μg/kg in the Phase 1 study, the RP2D was determined to be 360 μg/kg.
A total of 26 patients received IBI3003 at 360 μg/kg, with a median follow-up duration of 7.57 months. mPFS was not reached yet.
The overall response rate (ORR) was 84.6% , including 11 cases of stringent complete response (sCR), 4 cases of very good partial response (VGPR), and 7 cases of partial response (PR). The ORR was 94.7% among 19 patients who had received 2 to 4 prior lines of therapy, 87.5% among 8 patients with non-bone-related EMD, and 92.3% among 13 patients without EMD.
The median time to first response was 0.99 months (range: 0.9-8.3 months), the median time to first response of ≥VGPR was 1.87 months (range: 0.9-4.6 months), and the median time to first response of ≥CR was 2.79 months (range: 0.9-9.2 months).
Among patients who achieved CR or better as assessed by central laboratory next-generation sequencing (NGS) testing, the minimal residual disease (MRD) negativity rate was 100% (n=8) . Three patients achieved MRD negativity after receiving only one treatment cycle.
Manageable Safety Profile of IBI3003 in Patients with R/R MM
Hematologic toxicities were the most common Grade ≥3 treatment-related adverse events (TRAEs), occurring primarily during the dose-escalation phase and being manageable and reversible.
The incidences of CRS and immune effector cell-associated neurotoxicity syndrome (ICANS) were 52% and 3.9%, respectively. All events were Grade 1-2 and resolved with treatment. Prophylactic use of tocilizumab may reduce the risk of CRS.
The incidence of infections was 42.2%, with Grade ≥3 infections reported in 26.5% of patients.
For GPRC5D target-related TEAEs involving the oral cavity, skin, and nails, no Grade ≥3 oral TEAEs were observed. Most skin and nail TEAEs were Grade 1-2, with only two patients experiencing Grade 3 rash.
Potent and Sustained Pharmacodynamic Responses Observed with IBI3003 in Patients with R/R MM
Biomarker analyses showed a significant and sustained decline in serum soluble BCMA (sBCMA) levels across the IBI3003 120 μg/kg, 360 μg/kg, and 540 μg/kg dose groups.
Deep and durable reductions in sBCMA levels were observed across all dose groups. After three treatment cycles, the median reduction from baseline in sBCMA levels was 98.38% in the IBI3003 360 μg/kg group.
IBI3003 continued to demonstrate encouraging and durable responses, together with a manageable safety profile, in heavily pretreated patients with R/R MM. These efficacy and safety data support further evaluation of the clinical value of IBI3003 in the ongoing Phase 3 clinical study.
Professor Peng Liu of Zhongshan Hospital Affiliated to Fudan University stated, "Patients with R/R MM have a poor prognosis after failing treatments including PIs, IMiDs, and anti-CD38-based therapies, with an ORR of only 29.8%, a median progression-free survival of 4.6 months, and a median overall survival of 12.4 months [1] . Although bispecific antibodies are reshaping the treatment landscape of R/R MM, trispecific antibodies targeting two antigens simultaneously may help overcome treatment resistance caused by intra-tumor and inter-tumor heterogeneity, as well as treatment-induced antigen escape. A substantial unmet clinical need remains in R/R MM, particularly among heavily pretreated and high-risk patients.
The dual-target coverage of BCMA and GPRC5D by IBI3003 addresses antigen expression heterogeneity and treatment resistance associated with single-target therapies, thereby reducing tumor escape. Its optimized CD3 affinity enables precise T-cell activation and tumor killing while improving safety. In the Phase 1 results presented at this meeting, IBI3003 demonstrated a manageable safety profile and impressive efficacy at the 360 μg/kg dose, with an ORR of 84.6%. Significant efficacy was also observed in patients with EMD or other high-risk features, fully demonstrating the potential of IBI3003 to overcome treatment resistance. The ORR reached 94.7% among patients who had received 2 to 4 prior lines of therapy. We look forward to the results of the ongoing Phase 3 clinical study of IBI3003."
About IBI3003 (Anti-GPRC5D/BCMA/CD3 Trispecific Antibody)
IBI3003 was developed using Innovent's proprietary Sanbody® platform. It is a novel trispecific antibody targeting G protein-coupled receptor C5D (GPRC5D), B-cell maturation antigen (BCMA), and CD3. The molecule was designed to overcome tumor escape caused by the loss or downregulation of a single tumor antigen. In preclinical mouse models, IBI3003 demonstrated superior in vivo anti-tumor activity compared with marketed benchmark bispecific antibodies. It also demonstrated particularly prominent tumor-killing activity in in vitro cell models with low expression of BCMA and GPRC5D.
Phase 1/2 clinical trials of IBI3003 (NCT06083207 and NCT07336472) are being conducted concurrently in China, Australia, and the United States to evaluate its safety, tolerability, and efficacy in patients with R/R MM. In China, IBI3003 has advanced into a pivotal registrational clinical stage. TriadicMM-1 (NCT07623798) is a multicenter, randomized, open-label Phase 3 study designed to compare the efficacy and safety of IBI3003 with investigator's choice of therapy in patients with R/R MM who have received 1 to 4 prior lines of therapy. The primary endpoint is progression-free survival (PFS) assessed by an independent review committee (IRC). In addition, the Phase II study of IBI3003 combined with CD38 monoclonal antibody for frontline MM is also ongoing (NCT07764861).
About Innovent
Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 20 products in the market. It has 1 asset under NMPA review, 5 assets in phase 3 or pivotal clinical trials, and 20 more molecules in early clinical stage.
Innovent has entered into more than 30 strategic partnerships with global players such as Eli Lilly, Roche, Takeda, Pfizer, Sanofi, Incyte, and MD Anderson Cancer Center, representing an aggregate value of over RMB 350 billion. These efforts have set a benchmark for the high-quality outbound internationalization of China's innovative drug industry.
Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible.
For more information, visit www.innoventbio.com , or follow Innovent on Facebook and LinkedIn .
Statement: 1) Innovent does not recommend the use of any unapproved drug (s)/indication (s). 2) Ramucirumab (Cyramza®) and selpercatinib (Retsevmo®), pirtobrutinib (Jaypirca®) and abemaciclib (Verzenios®) were developed by Eli Lilly and Company. Disclaimer: Innovent does not recommend any off-label usage.
Forward-Looking Statements of Innovent Biologics
This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.
These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent's competitive environment and political, economic, legal and social conditions.
Contact of Innovent Biologics
Media: pr@innoventbio.com; +86 512-69566088
Investor: ir@innoventbio.com; +86 512-69566088
Reference:
[1] Mateos M , Weisel K , Stefano V D ,et al.LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma[J].Leukemia, 2022, 36:1371 - 1376.DOI:10.1038/s41375-022-01531-2.
IBI3003 is a novel trispecific antibody targeting G protein-coupled receptor C5D (GPRC5D), B-cell maturation antigen (BCMA), and CD3. Its dual-targeting design against BCMA and GPRC5D is intended to overcome tumor escape caused by the loss or downregulation of a single tumor antigen. In preclinical mouse models, IBI3003 demonstrated superior in vivo anti-tumor activity compared with marketed benchmark bispecific antibodies targeting GPRC5D/CD3 or BCMA/CD3, with particularly prominent tumor-killing activity in in vitro cell models with low expression of BCMA and GPRC5D. Currently, Innovent is conducting Phase 1/2 clinical trials of IBI3003 in China, Australia, and the United States (NCT06083207 and NCT07336472) to evaluate its safety, tolerability, and preliminary efficacy in patients with R/R MM. In parallel, Innovent has advanced the Phase 3 TriadicMM-1 study (NCT07623798) in China for IBI3003 in patients with R/R MM who have received 1 to 4 prior lines of therapy. In addition, the Phase II study of IBI3003 combined with CD38 monoclonal antibody for frontline MM is also ongoing (NCT07764861).
The updated data were from the Phase 1 clinical study NCT06083207, which enrolled eligible patients with R/R MM who had failed at least two prior lines of therapy, including at least one proteasome inhibitor (PI), one immunomodulatory drug (IMiD), and one anti-CD38-based therapy, and who had relapsed or were refractory to their last anti-myeloma regimen. Patients with prior BCMA- and/or GPRC5D-targeted therapy were also eligible for enrollment. IBI3003 was administered subcutaneously once weekly (QW). Patients who received continuous treatment for ≥6 months and achieved a partial response (PR) or better for ≥2 months could switch to once-every-two-weeks (Q2W) dosing for maintenance. To reduce the risk of cytokine release syndrome (CRS), 1 to 3 priming doses were incorporated into the study design.
A total of 102 patients were enrolled in this phase of the study in China and Australia, with doses ranging from 0.1 μg/kg to 800 μg/kg. The median patient age was 62 years (range: 40-88), 37.1% of patients were classified as high risk according to mSMART criteria, and 53.9% had ≥1 site of extramedullary disease (EMD). The median number of prior lines of therapy was 4 (range: 2-12). All patients had received at least three classes of therapy, including a PI, an IMiD, and an anti-CD38 antibody. Among them, 55.9% had received at least five classes of therapy, including at least two PIs, two IMiDs, and one anti-CD38 antibody; 33.3% had previously received anti-BCMA and/or anti-GPRC5D therapies; and 88.2% were refractory to their last treatment. As of the data cutoff date of June 30, 2026, the median follow-up duration was 6.65 months (range: 0.8-15.2).
Rapid, Deep, and Durable Responses Observed with IBI3003 at 360 μg/kg
Based on an integrated analysis of the efficacy, safety, and pharmacokinetic/pharmacodynamic (PK/PD) data from dose optimization cohorts receiving IBI3003 at 120, 360, and 540 μg/kg in the Phase 1 study, the RP2D was determined to be 360 μg/kg.
A total of 26 patients received IBI3003 at 360 μg/kg, with a median follow-up duration of 7.57 months. mPFS was not reached yet.
The overall response rate (ORR) was 84.6% , including 11 cases of stringent complete response (sCR), 4 cases of very good partial response (VGPR), and 7 cases of partial response (PR). The ORR was 94.7% among 19 patients who had received 2 to 4 prior lines of therapy, 87.5% among 8 patients with non-bone-related EMD, and 92.3% among 13 patients without EMD.
The median time to first response was 0.99 months (range: 0.9-8.3 months), the median time to first response of ≥VGPR was 1.87 months (range: 0.9-4.6 months), and the median time to first response of ≥CR was 2.79 months (range: 0.9-9.2 months).
Among patients who achieved CR or better as assessed by central laboratory next-generation sequencing (NGS) testing, the minimal residual disease (MRD) negativity rate was 100% (n=8) . Three patients achieved MRD negativity after receiving only one treatment cycle.
Manageable Safety Profile of IBI3003 in Patients with R/R MM
Hematologic toxicities were the most common Grade ≥3 treatment-related adverse events (TRAEs), occurring primarily during the dose-escalation phase and being manageable and reversible.
The incidences of CRS and immune effector cell-associated neurotoxicity syndrome (ICANS) were 52% and 3.9%, respectively. All events were Grade 1-2 and resolved with treatment. Prophylactic use of tocilizumab may reduce the risk of CRS.
The incidence of infections was 42.2%, with Grade ≥3 infections reported in 26.5% of patients.
For GPRC5D target-related TEAEs involving the oral cavity, skin, and nails, no Grade ≥3 oral TEAEs were observed. Most skin and nail TEAEs were Grade 1-2, with only two patients experiencing Grade 3 rash.
Potent and Sustained Pharmacodynamic Responses Observed with IBI3003 in Patients with R/R MM
Biomarker analyses showed a significant and sustained decline in serum soluble BCMA (sBCMA) levels across the IBI3003 120 μg/kg, 360 μg/kg, and 540 μg/kg dose groups.
Deep and durable reductions in sBCMA levels were observed across all dose groups. After three treatment cycles, the median reduction from baseline in sBCMA levels was 98.38% in the IBI3003 360 μg/kg group.
IBI3003 continued to demonstrate encouraging and durable responses, together with a manageable safety profile, in heavily pretreated patients with R/R MM. These efficacy and safety data support further evaluation of the clinical value of IBI3003 in the ongoing Phase 3 clinical study.
Professor Peng Liu of Zhongshan Hospital Affiliated to Fudan University stated, "Patients with R/R MM have a poor prognosis after failing treatments including PIs, IMiDs, and anti-CD38-based therapies, with an ORR of only 29.8%, a median progression-free survival of 4.6 months, and a median overall survival of 12.4 months [1] . Although bispecific antibodies are reshaping the treatment landscape of R/R MM, trispecific antibodies targeting two antigens simultaneously may help overcome treatment resistance caused by intra-tumor and inter-tumor heterogeneity, as well as treatment-induced antigen escape. A substantial unmet clinical need remains in R/R MM, particularly among heavily pretreated and high-risk patients.
The dual-target coverage of BCMA and GPRC5D by IBI3003 addresses antigen expression heterogeneity and treatment resistance associated with single-target therapies, thereby reducing tumor escape. Its optimized CD3 affinity enables precise T-cell activation and tumor killing while improving safety. In the Phase 1 results presented at this meeting, IBI3003 demonstrated a manageable safety profile and impressive efficacy at the 360 μg/kg dose, with an ORR of 84.6%. Significant efficacy was also observed in patients with EMD or other high-risk features, fully demonstrating the potential of IBI3003 to overcome treatment resistance. The ORR reached 94.7% among patients who had received 2 to 4 prior lines of therapy. We look forward to the results of the ongoing Phase 3 clinical study of IBI3003."
About IBI3003 (Anti-GPRC5D/BCMA/CD3 Trispecific Antibody)
IBI3003 was developed using Innovent's proprietary Sanbody® platform. It is a novel trispecific antibody targeting G protein-coupled receptor C5D (GPRC5D), B-cell maturation antigen (BCMA), and CD3. The molecule was designed to overcome tumor escape caused by the loss or downregulation of a single tumor antigen. In preclinical mouse models, IBI3003 demonstrated superior in vivo anti-tumor activity compared with marketed benchmark bispecific antibodies. It also demonstrated particularly prominent tumor-killing activity in in vitro cell models with low expression of BCMA and GPRC5D.
Phase 1/2 clinical trials of IBI3003 (NCT06083207 and NCT07336472) are being conducted concurrently in China, Australia, and the United States to evaluate its safety, tolerability, and efficacy in patients with R/R MM. In China, IBI3003 has advanced into a pivotal registrational clinical stage. TriadicMM-1 (NCT07623798) is a multicenter, randomized, open-label Phase 3 study designed to compare the efficacy and safety of IBI3003 with investigator's choice of therapy in patients with R/R MM who have received 1 to 4 prior lines of therapy. The primary endpoint is progression-free survival (PFS) assessed by an independent review committee (IRC). In addition, the Phase II study of IBI3003 combined with CD38 monoclonal antibody for frontline MM is also ongoing (NCT07764861).
About Innovent
Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 20 products in the market. It has 1 asset under NMPA review, 5 assets in phase 3 or pivotal clinical trials, and 20 more molecules in early clinical stage.
Innovent has entered into more than 30 strategic partnerships with global players such as Eli Lilly, Roche, Takeda, Pfizer, Sanofi, Incyte, and MD Anderson Cancer Center, representing an aggregate value of over RMB 350 billion. These efforts have set a benchmark for the high-quality outbound internationalization of China's innovative drug industry.
Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible.
For more information, visit www.innoventbio.com , or follow Innovent on Facebook and LinkedIn .
Statement: 1) Innovent does not recommend the use of any unapproved drug (s)/indication (s). 2) Ramucirumab (Cyramza®) and selpercatinib (Retsevmo®), pirtobrutinib (Jaypirca®) and abemaciclib (Verzenios®) were developed by Eli Lilly and Company. Disclaimer: Innovent does not recommend any off-label usage.
Forward-Looking Statements of Innovent Biologics
This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.
These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent's competitive environment and political, economic, legal and social conditions.
Contact of Innovent Biologics
Media: pr@innoventbio.com; +86 512-69566088
Investor: ir@innoventbio.com; +86 512-69566088
Reference:
[1] Mateos M , Weisel K , Stefano V D ,et al.LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma[J].Leukemia, 2022, 36:1371 - 1376.DOI:10.1038/s41375-022-01531-2.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。